CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 4,757 enrolled
Drug / intervention
Antioxidants +2 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000145
NCT00000145Phase 3Completed
CompareCT.gov

Age-Related Eye Disease Study (AREDS)

National Eye Institute (NEI)·interventional·Posted Sep 24, 1999·Updated Jan 23, 2009

In Brief

A Phase 3 clinical trial evaluating Antioxidants, Zinc, and 1 other intervention for Macular Degeneration and 2 related conditions. Completed, enrolled 4,757 participants.

Detailed Summary

To assess the clinical course, prognosis, and risk factors of age-related macular degeneration (AMD) and cataract. To evaluate, in randomized clinical trials, the effects of pharmacologic doses of (1) antioxidants and zinc on the progression of AMD and (2) antioxidants on the development and progression of lens opacities.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration, Cataract, Lens Opacities
Countries--
CollaboratorsBausch & Lomb Incorporated

Timeline

Phase 3CompletedFinished
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 24, 1999
Enrollment StartSep 1, 1990
Primary CompletionOct 1, 2001
Study CompletionDec 1, 2006
TodayJul 2, 2026
Enrollment to primary: 11.1 yearsPosted 26.8 years ago

Interventions

Antioxidantsdietary

500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene

Zincdietary

80 milligrams zinc oxide; 2 milligrams of cupric oxide

Antioxidants and zincdietary

500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene; 80 milligrams zinc oxide; 2 milligrams of cupric oxide